Athersys: A Significantly Undervalued Stem Cell Company Approaching Key Catalysts

I suggest investors take a look at an under-followed company called Athersys (NASDAQ:ATHX). After decades of debate on the ethics of stem cell research, the rhetoric has ebbed and focus has shifted from ethics to the promises of clinical development. Companies all over the globe are now treading into the promising world of stem cells. Investors need to rethink this investment arena, and Athersys is one of the companies they should seriously consider.

While the bulls have long fantasized about huge profits from a miracle stem cell drug, the bears have consistently used facts about stem cell toxicities and their nascent state in the FDA drug development process to explain their reticence to jump onto stem cells' commercial...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details